Home   ->   services & solutions   ->   Discovery Services   ->   Biology   ->   CMD

WuXi Cardiovascular and Metabolic Disease (CMD)

  • In vitro Services for Cardiovascular and Metabolic Diseases (CMD)

    • Service Provided

      • Assay development and execution
      • Compound screen and profiling
      • Medchem programs support
      • Mechanism of action (MOA) studies
    • Target Family

      • GPCR/Receptor
      • Enzyme
      • Transporter
      • Antibody
      • Biomarker
    • Technology Platform

      • Radioactivity assays
      • Fluorescence assays
      • Luminescence assays
      • Electochemiluminescence assays
      • PCR
      • Western blot
      • Isoelectric focusing electrophoresis (IEF)
      • SPR (Biacore), ITC
  • In vivo Services for Cardiovascular and Metabolic Diseases(CMD)

    • Obesity

      • Acute food intake, chronic food intake and BW studies; growing or established DIO mice; multiple clinical readouts
    • Diabetes

      • oGTT (mouse/rat), ipGTT (mouse/rat), ivGTT (rat); glucosuria
      • Chronic efficacy studies in db/db and other hyperglycemic models; chronic efficacy studies for improvement of insulin sensitivity
    • Dyslipidemia

      • Acute lipid tolerance
      • Chronic studies for triglyceride and cholesterol levels
    • Hypertension

      • Blood pressure measurement in telemetrized rats
      • (Na/K) diuresis
    • Nephropathy

      • Proteinuria; natriuresis
      • Podocyte injury induced kidney injury
      • Cisplatin-induced kidney injury
    • Thrombosis

      • Rat arteriovenous shunt model
      • Rat tail bleeding model
    • Obesity and Diabetes

      1. Summary of established capabilities at WuXi CMD

      2. Diet induced obese mouse model: Case Study

      • Male C57BL/6J mice, 6 weeks old
      • Fed on high fat diet (HFD; 60% kcal) for 12-20 weeks
      • Food intake and body weights measured once a week during feeding period

      3. 14-day subchronic efficacy study with multiple endpoints in DIO mice: Case Study
      Standard efficacy study paradigm:

      • Singly house prior to PO vehicle acclimation
      • Test compound dosing via PO
      • Daily body weight/food intake measurement
      • Pair feeding available
      • Blood glucose, lipid profile
      • Glucose or insulin tolerance test (GTT or ITT)
      • PK/PD correlation analysis

      4. Chronic efficacy study in db/db mice: Case Study

    • Dyslipidemia: Case Study of Lipid Tolerance Test (LTT)

    • Hypertension: Case Study of Spontaneously Hypertensive Rat (SHR) Telemetry

    • Nephropathy: Case Study of PAN-Induced Proteinuria

    • Thrombosis: Case Study of Rat Arteriovenous Shunt Model